BE902626A - Nouvelle forme galeinique retard. - Google Patents

Nouvelle forme galeinique retard.

Info

Publication number
BE902626A
BE902626A BE1/011271A BE1011271A BE902626A BE 902626 A BE902626 A BE 902626A BE 1/011271 A BE1/011271 A BE 1/011271A BE 1011271 A BE1011271 A BE 1011271A BE 902626 A BE902626 A BE 902626A
Authority
BE
Belgium
Prior art keywords
matrix
galeinic
water
agent
new delayed
Prior art date
Application number
BE1/011271A
Other languages
English (en)
Original Assignee
Sandoz Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Sa filed Critical Sandoz Sa
Publication of BE902626A publication Critical patent/BE902626A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention a pour objet une dispersion solide d'un agent ayant une activité pharmacologique, dans un matrice cristalline soluble dans l'eau servant d'excipient, caractérisée en ce que l'agent : a) a une solublilité maximale dans l'eau de 0,01% à 37 degrés C, b) est présent dans la matrice à une concentration supérieure à 5 % en poids, c) est présent dans la matrice à une concentration supérieure à 5 % en poids sous une forme cristalline cohérente. Structure secondaire d'un agent actif résultant de l'extraction de la matrice, par exemple avec de l'eau.
BE1/011271A 1984-06-14 1985-06-10 Nouvelle forme galeinique retard. BE902626A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3422083 1984-06-14
DE3442566 1984-11-22

Publications (1)

Publication Number Publication Date
BE902626A true BE902626A (fr) 1985-12-10

Family

ID=25822108

Family Applications (1)

Application Number Title Priority Date Filing Date
BE1/011271A BE902626A (fr) 1984-06-14 1985-06-10 Nouvelle forme galeinique retard.

Country Status (21)

Country Link
AT (1) AT391806B (fr)
AU (2) AU587190B2 (fr)
BE (1) BE902626A (fr)
CA (1) CA1264441A (fr)
CY (1) CY1635A (fr)
DE (1) DE3520184C2 (fr)
DK (1) DK167649B1 (fr)
ES (1) ES8702141A1 (fr)
FR (1) FR2565822B1 (fr)
GB (3) GB2160100B (fr)
GR (1) GR851430B (fr)
HK (1) HK25192A (fr)
HU (1) HU198844B (fr)
IE (1) IE58834B1 (fr)
IL (1) IL75490A0 (fr)
IT (1) IT1200080B (fr)
LU (1) LU85946A1 (fr)
NL (1) NL194389C (fr)
NZ (1) NZ212390A (fr)
PT (1) PT80635B (fr)
SE (1) SE504583C2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
AU3432689A (en) * 1988-03-24 1989-10-16 Bukh Meditec A/S Controlled release composition
GR1000270B (el) * 1988-09-30 1992-05-12 Alza Corp Μορφη δοσολογιας για θεραπεια καρδιαγγειακων ασθενειων.
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
DE4201179A1 (de) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
WO1998001117A1 (fr) 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Matrice a liberation prolongee pour medicaments insolubles en doses elevees
DE19710009A1 (de) * 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
EP1189599A2 (fr) * 1999-06-11 2002-03-27 Eli Lilly And Company Materiaux pharmaceutiques, leurs techniques de preparation et leurs utilisations
JP3462490B2 (ja) * 1999-08-04 2003-11-05 山之内製薬株式会社 安定な経口用医薬組成物
JP3893058B2 (ja) 1999-09-30 2007-03-14 ペンウェスト ファーマシューティカルズ カンパニー 高度に可溶性の薬物のための徐放性マトリックス系
BR0206825A (pt) * 2001-02-13 2004-02-25 Astrazeneca Ab Formulação de dispersão sólida de liberação modificada, multiparticulada, processo para a preparação da formulação, uso da mesma, tablete, e, métodos para o tratamento de uma doença cardiovascular, e, para o tratamento de câncer
US7135436B2 (en) 2003-05-05 2006-11-14 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
EP1690528A1 (fr) 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Procedé pour la préparation des formes de dosage comprenant une dispersion solide d'un agent active microcristalline
JP2010511713A (ja) 2006-12-05 2010-04-15 ランデック コーポレイション 薬物送達
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
MX2011001864A (es) 2008-08-20 2011-06-20 Univ Texas Extrusion de fusion en caliente de multiples particulas de liberacion modificada.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617362A1 (de) * 1967-11-17 1971-03-25 Beiersdorf Ag Verfahren zur Herstellung von Arzneimitteln mit verzoegerter Wirkstoffabgabe in Form von Kapseln
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
DE2549740A1 (de) * 1975-11-17 1977-05-18 Sandoz Ag Neue galenische formen und verfahren zu deren herstellung
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
DK149855C (da) * 1977-06-20 1987-04-21 Sandoz Ag Analogifremgangsmaade til fremstilling af 1,4-dihydropyridinderivater
EP0001247A1 (fr) * 1977-09-14 1979-04-04 Kanebo, Ltd. Composition pharmaceutique contenant de la nifédipine et procédé pour sa préparation.
WO1980001242A1 (fr) * 1978-12-21 1980-06-26 Sandoz Ag Preparations galeniques
DE2904310A1 (de) * 1979-02-05 1980-08-07 Boehringer Mannheim Gmbh Formlinge mit retardierter wirkstofffreisetzung und verfahren zu deren herstellung
JPS56115726A (en) * 1980-02-20 1981-09-11 Kaken Pharmaceut Co Ltd Pharmaceutical containing nifedipine
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
US4442112A (en) * 1981-09-02 1984-04-10 Sandoz Ltd. Dihydropyridine derivatives useful in treating vascular headaches
DE3270785D1 (en) * 1981-10-29 1986-05-28 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
CA1208558A (fr) * 1982-10-07 1986-07-29 Kazuo Kigasawa Medicament oral
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung

Also Published As

Publication number Publication date
PT80635B (pt) 1987-10-20
IT1200080B (it) 1989-01-05
HK25192A (en) 1992-04-10
PT80635A (en) 1985-07-01
GB8514855D0 (en) 1985-07-17
FR2565822A1 (fr) 1985-12-20
LU85946A1 (fr) 1986-01-24
DK264785D0 (da) 1985-06-12
GB8727056D0 (en) 1987-12-23
DK264785A (da) 1985-12-15
GB8727055D0 (en) 1987-12-23
GB2196852A (en) 1988-05-11
GB2196852B (en) 1989-05-17
IT8548210A0 (it) 1985-06-13
GB2160100B (en) 1989-06-01
NZ212390A (en) 1992-02-25
FR2565822B1 (fr) 1989-02-17
SE504583C2 (sv) 1997-03-10
NL194389C (nl) 2002-03-04
DE3520184C2 (de) 1997-03-13
AT391806B (de) 1990-12-10
IE851460L (en) 1985-12-14
ATA174885A (de) 1990-06-15
ES544075A0 (es) 1987-01-01
AU4348685A (en) 1985-12-19
GR851430B (fr) 1985-11-25
CY1635A (en) 1992-11-06
ES8702141A1 (es) 1987-01-01
NL8501578A (nl) 1986-01-02
DK167649B1 (da) 1993-12-06
HUT40918A (en) 1987-03-30
AU587190B2 (en) 1989-08-10
GB2196851A (en) 1988-05-11
SE8502950L (sv) 1985-12-15
IE58834B1 (en) 1993-11-17
IL75490A0 (en) 1985-10-31
CA1264441A (fr) 1990-01-16
NL194389B (nl) 2001-11-01
SE8502950D0 (sv) 1985-06-13
DE3520184A1 (de) 1985-12-19
GB2196851B (en) 1989-06-07
GB2160100A (en) 1985-12-18
AU4454389A (en) 1990-03-22
HU198844B (en) 1989-12-28

Similar Documents

Publication Publication Date Title
BE902626A (fr) Nouvelle forme galeinique retard.
KR840000236A (ko) 포유류의 국부용 제형의 수분 손실량을 극소화시키는 방법
IE39898B1 (en) 1-or 7-oxoalkyl xanthine derivatives
NZ214305A (en) Inhibiting the precipitation and deposition of alkaline earth metal scales in aqueous systems using an anionic polyelectrolyte and an anionic surfactant
FR2426731A1 (fr) Compositions tensio-actives aqueuses et concentrees
BE899779A (fr) Composition detergente liquide a une seule phase, stabilisee, chargee d'adjuvant de detergence et contenant des enzymes.
Mandl et al. Epinephrine and glucagon counteract inhibition of protein synthesis induced by D-galactosamine in isolated mouse hepatocytes
ES461077A1 (es) Procedimiento para la preparacion de 2-bencilpirrolidinas.
DE3277731D1 (en) Solid, strong alcaline compounds that contain active chlorine
JPS5429102A (en) Impeller of pump with high water head
Rastogi et al. Nucleic acid and protein content of the frog pars distalis and hypothalamus during the annual reproductive cycle
JPS57185219A (en) Remedy for cancer
ES8500897A1 (es) Un procedimiento para la preparacion de una composicion de oxido de amina.
GB1047267A (fr)
JPS52120911A (en) Prevention of crack at grain boundary at high temperature
JPS5616699A (en) Electrolytic polishing method for austenitic stainless steel containing nickel and nickel base alloy by neutral electrolyte
Cupr et al. Electrochemical Protection of Structural Steels
Cheesewright EEC Steel Output Rises Only 1% in First Half of Year.(1985)
Shmurygina et al. The Formation and Behavior of Fluoroaluminates of Alkaline and Alkaline-Earth Metals in Zinc Sulfate Solutions
TANAKA et al. Effects of Some Food Additives on Protein Biosynthesis by Rat Liver Slice and Cell-Free System (Part 2)
JPS5277079A (en) Preparation of spiro compound
JPS5297909A (en) Preparation of perfluoroacrylic acid derivatives
Hilgenfeldt et al. Some Aspects of the Increased Use of Secondary Aluminum Alloys for Pressure Die Casting
JPS56126440A (en) Emulsification stabilizing assistant
JPS53119822A (en) Preparation of 2-dimethylaminoethylisothiocyanate

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *NOVARTIS A.G.

Effective date: 20050610

RE20 Patent expired

Owner name: *NOVARTIS A.G.

Effective date: 20050610